Category: biotech

.Just a handful of short full weeks after winning an FDA Fast Track tag for its own investigational BTK degrader in certain blood stream cancers

.AbbVie has returned to the source of its antipsychotic goliath Vraylar in search of one more smash hit, paying $25 million beforehand to make up

.On the very same day that some Parkinson’s illness drugs are actually being actually disputed, AbbVie has actually announced that its own late-stage monotherapy candidate

.AstraZeneca has actually made use of artificial intelligence to devise a special biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), wanting to differentiate the

.Monopar Therapeutics is bouncing back a medicine coming from the scrap heap of AstraZeneca’s rare condition pipe. It has accredited ALXN-1840, a candidate for the